F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comDivi's Laboratories Ltd is one of India’s leading pharmaceutical companies known for its strong presence in active pharmaceutical ingredients (APIs) and intermediates. The company enjoys global recognition for quality, compliance, and research capabilities. Investors are increasingly interested in the growth journey of Divi’s Laboratories Ltd share price from 2025 to 2030, especially as demand for high-quality pharma exports continues to rise.
In this detailed blog, we explore Divi’s Laboratories Ltd Share Price Target from 2025 to 2030, based on current statistics, expert predictions, and market movements. The goal is to help investors evaluate whether Divi’s is a strong long-term investment opportunity.
Before moving to future projections, let’s take a look at the most recent stock performance of Divi’s Laboratories Ltd, sourced from Screener.in and Moneycontrol.com:
Open: ₹6,551.00
Previous Close: ₹6,616.00
Volume: 5,45,217
Value (Lacs): ₹36,300.55
VWAP: ₹6,654.44
Beta: 0.71
Market Capitalization: ₹1,76,748 Crores
High: ₹6,694.00
Low: ₹6,551.00
52-Week High: ₹6,862.50
52-Week Low: ₹4,395.30
All-Time High: ₹6,862.50
All-Time Low: ₹38.75
Face Value: ₹2.00
Promoters: 51.89%
Foreign Institutions: 18.01%
Mutual Funds: 12.83%
Retail and Others: 9.39%
Other Domestic Institutions: 7.88%
Based on current valuation, business outlook, and expert projections, here is the estimated share price target for Divi’s Labs over the coming years:
| Year | Share Price Target (₹) |
|---|---|
| 2025 | ₹6,600 – ₹7,300 |
| 2026 | ₹6,800 – ₹7,600 |
| 2027 | ₹7,100 – ₹8,000 |
| 2028 | ₹7,400 – ₹8,500 |
| 2029 | ₹7,800 – ₹9,000 |
| 2030 | ₹8,200 – ₹9,600 |
These predictions are based on increasing global pharmaceutical demand, company expansion plans, and consistent revenue growth.
In 2025, the expected price range is ₹6,600 to ₹7,300. The company is poised for growth due to:
Strong demand for APIs from regulated markets.
Continued momentum in export orders.
High promoter holding reflecting confidence and stability.
By 2026, the share price may range between ₹6,800 and ₹7,600, driven by:
Expansion of manufacturing facilities.
Rising contribution from custom synthesis contracts.
Growth in the nutraceuticals business.
In 2027, the forecast ranges from ₹7,100 to ₹8,000. Key factors include:
Increased collaboration with global pharma companies.
Entry into newer therapeutic segments.
Higher margins from specialty products.
The share price in 2028 is expected to be between ₹7,400 to ₹8,500. This will likely be the result of:
Scaling up exports to Europe and the US.
Advanced API research and innovation.
Sustainable compliance practices and eco-friendly manufacturing.
For 2029, estimates suggest a price range of ₹7,800 to ₹9,000, influenced by:
Adoption of green chemistry and continuous manufacturing.
Strong order inflows from the global pharmaceutical pipeline.
New capacity additions and backward integration.
By 2030, the projected share price is ₹8,200 to ₹9,600, reflecting long-term consistent performance and:
Leadership in the API export segment.
Cutting-edge infrastructure and technology.
Stable revenue and profit growth supported by global demand.
| Fiscal Year | Revenue (₹ Crores) | Net Profit (₹ Crores) |
|---|---|---|
| FY23 | 8,963 | 2,144 |
| FY24 (Est.) | 9,900 | 2,350 |
Growing global demand for affordable and high-quality APIs is a strong tailwind for Divi’s Laboratories.
With over 50% promoter holding, the company shows high internal trust and long-term vision.
With a beta of just 0.71, the stock is less volatile, making it a good option for conservative investors.
More than 85% of the company’s revenue comes from exports, especially to US and Europe, making it globally competitive.
Continuous investment in research gives Divi’s Labs a competitive edge in developing complex molecules.
The company has a good history of regulatory compliance, which boosts investor confidence.
Q1: What is the share price target for Divi's Laboratories Ltd in 2025?
The estimated target for 2025 is between ₹6,600 to ₹7,300.
Q2: What is the projected share price for 2030?
By 2030, the share price is expected to reach between ₹8,200 to ₹9,600.
Q3: Is Divi’s Laboratories a good long-term investment?
Yes, due to its global presence, low volatility, and strong fundamentals, Divi’s is seen as a safe long-term stock.
Q4: What are the risks involved in investing in Divi’s Laboratories?
Risks include regulatory changes, fluctuations in export demand, and pricing pressure from global competitors.
Divi's Laboratories Ltd stands strong as a trusted player in the Indian pharmaceutical export market. Between 2025 and 2030, the stock is projected to rise steadily due to its research strength, expanding global footprint, and regulatory compliance. For investors seeking long-term gains with comparatively lower risk, Divi’s Laboratories offers a solid opportunity backed by numbers and fundamentals.
As always, before investing, investors should consider market trends, company reports, and expert insights to make informed decisions. Divi’s Laboratories is well-positioned to ride the next wave of global pharma growth while delivering consistent shareholder value.
Register & Login